Table 1.
Clinical and epidemiological characteristics of HIV/HCV-coinfected patients stratified by values of LSM.
| Characteristic | <12.5 kPa | 12.5–25 kPa | >25 kPa | p |
|---|---|---|---|---|
| No. | 102 | 65 | 39 | - |
| Age (years) | 48 (45; 52) | 49 (46; 51) | 50 (46; 53) | 0.287 |
| Gender (male) | 83 (81.4%) | 47 (72.3%) | 32 (82.1%) | 0.320 |
| BMI (kg/m2) | 23.8 (21.4; 26.1) | 25.1 (22.7; 28.1) | 24.5 (21.8; 26.5) | 0.077 |
| Diabetes | 8 (7.8%) | 5 (7.7%) | 5 (12.8%) | 0.605 |
| Current alcohol drinker (>50 g/day) | 2 (2%) | 3 (4.6%) | 1 (2.6%) | 0.603 |
| Alcohol ex-drinker | 47 (46.1%) | 31 (47.7%) | 23 (59%) | 0.399 |
| HIV acquired by IVDU | 79 (77.5%) | 49 (77.4%) | 32(82.1%) | 0.570 |
| Prior AIDS | 21 (20.6%) | 20 (30.8%) | 13 (34.2%) | 0.276 |
| Years since HIV diagnosis | 23 (17; 26) | 24 (20; 26) | 21 (17; 25) | 0.098 |
| Years since HCV infection | 22 (16; 24) | 21 (18; 26) | 18 (17; 22) | 0.170 |
| Previous IFNα HCV-therapy | 33 (32.4%) | 46 (70.8%) | 19 (48.7%) | 0.001 |
| Antiretroviral therapy | ||||
| Non-treated | 1 (1%) | 0 (0%) | 2 (5.3%) | 0.122 |
| PI-based | 15 (14.7%) | 11 (16.9%) | 3 (7.7%) | 0.432 |
| 2NRTI+II-based | 28 (27.5%) | 17 (26.2%) | 8 (20.5%) | 0.709 |
| 2NRTI+PI-based | 23 (22.5%) | 9 (13.8%) | 10 (26.3%) | 0.233 |
| 2NRTI+NNRTI-based | 29 (28.4%) | 23 (35.4%) | 12 (31.6%) | 0.689 |
| Others | 6 (5.9%) | 5 (7.7%) | 4 (10.2%) | 0.523 |
| HIV markers | ||||
| Nadir CD4+ T cells | 198 (99; 277) | 162 (83; 234) | 167 (84; 242) | 0.197 |
| Nadir CD4+ T cells < 200 cells/mm3 | 49 (48%) | 39 (60%) | 25 (64.1%) | 0.128 |
| Baseline CD4+ T cells | 626 (436; 845) | 511 (344; 730) | 506 (360; 803) | 0.023 |
| Baseline CD4+ T cells < 500 cells/mm3 | 33 (32.4%) | 31 (48.4%) | 19 (48.7%) | 0.062 |
| HCV markers | ||||
| HCV genotype | ||||
| 1 | 69 (67.6%) | 52 (80%) | 28 (71.8%) | 0.158 |
| 2 | 3 (2.9%) | 1 (1.5%) | 1 (2.6%) | 0.853 |
| 3 | 16 (15.7%) | 11 (16.9%) | 8 (20.5%) | 0. 764 |
| 4 | 14 (13.7%) | 1 (1.5%) | 2 (5.1%) | 0.016 |
| Log10 HCV-RNA (IU/mL) | 6.30 (5.81; 6.80) | 6.30 (6.00 6.68) | 6.11 (5.74; 6.56) | 0.472 |
| HCV-RNA > 850,000 IU/mL | 77 (75.5%) | 55 (84.6%) | 30 (76.9%) | 0.251 |
Statistics: Values expressed as absolute number (percentage) and median (interquartile range). p-values were calculated by Chi-square tests and Mann-Whitney tests in HIV/HCV-coinfected patients stratified by LSM (<12.5 kPa, 12.5–25 kPa, and >25 kPa). Abbreviations: LSM, liver stiffness measure; kPa, kilopascals; BMI, body mass index; HCV, hepatitis C virus; HCV-RNA, HCV plasma viral load; HIV-1, human immunodeficiency virus type 1; LSM, liver stiffness measure; HIV-RNA, HIV plasma viral load; IVDU, intravenous drug user; AIDS, acquired immune deficiency syndrome; IFNα+rib, interferon-alpha plus ribavirin; NNRTI, non-nucleoside analogue HIV reverse transcriptase inhibitor; NRTI, nucleoside analogue HIV reverse transcriptase inhibitor; PI, protease inhibitor; II, integrase inhibitor.